Gamma or beta radiation.

China PharmaHub signals distribution agreement for radioactive glass sphere treatment for liver cancer China PharmaHub Corp. , which includes recently merged with GLOBALLY Relics which has changed its name to China PharmaHub Corp, and can be along the way of obtaining approval from FINRA to trade under its fresh name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement with a global leader in precision glass technology which can be useful to manufacture high accuracy radioactive glass spheres that emit alpha, gamma or beta radiation, either or in mixture individually, for the treating malignant tumors of the liver. The Agreement gives PharmaHub the unique to marketplace in China, Hong Kong, Taiwan and Macau , Singapore, Malaysia, and Bangladesh this innovative liver malignancy treatment which is comparable to a FDA-accepted liver cancer therapy testosterone .